CNN
About this Deal
|
Johnson & Johnson's Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the company announced Friday. The vaccine was 72% effective against moderate and severe disease in the US, the company said. It's a striking difference from vaccines from Pfizer/BioNTech and Moderna, and it may give pause to people uncertain about which vaccine to get or when they can get one. The vaccines already on the market in the US are about 95% effective overall against symptomatic Covid-19, with perhaps even higher efficacy against severe cases. But experts say the Johnson & Johnson vaccine will still be useful against the pandemic in the United States and around the world. |
Download Our App
